Simon Lowth, Interim Chief Executive Officer at AstraZeneca, comments on the results. AZ’s core EPS target range for the full year is expected to maintain at US$5.85 to $6.15. This is largely ...

AstraZeneca on Thursday said it could face a fine of up to $4.5 million in China over suspected unpaid import taxes, raising ...

AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...

Simon Vickers was found guilty last month of killing his daughter Scarlett Vickers after stabbing her in the heart at their home in Darlington, County Durham, in July 2024. The 50-year-old ...

Simon Shuster is a senior correspondent at TIME. He covers international affairs, with a focus on Russia and Ukraine. For his first book, The Showman, he reported inside the Ukrainian President ...

we are taking another significant step towards reducing our carbon footprint and supporting the UK’s transition to a greener future,” said Simon Lowth, Chief Financial Officer, BT Group.

Taoiseach Simon Harris has said, after fake adverts with his image flooded X in recent days. Mr Harris has appeared to threaten legal action against Elon Musk after false adverts of news articles ...

AstraZeneca, said: "Our company delivered a very strong performance in 2024 with Total Revenue and Core EPS up 21% and 19% respectively. We also delivered nine positive high value Phase III ...

AstraZeneca Q4 revenue rose 18% to $14.89 billion, surpassing estimates, with oncology sales up 27% to $6.34 billion. FY25 guidance projects high single-digit revenue growth and low double-digit ...

AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities investigate the company’s former China head. AZ has received a notice ...

Investors with a lot of money to spend have taken a bullish stance on AstraZeneca AZN. And retail traders should know. We noticed this today when the positions showed up on publicly available ...

The government has defended its negotiations with AstraZeneca, after the pharmaceutical giant ditched a planned £450m investment last week, blaming a shortfall in government funding. Science ...